CD8A and colorectal carcinoma: In the present study, we analyzed the prognostic ability of the novel combination of CD8+ T-lymphocyte fraction and stroma fraction using digital pathology based automated assessment and integrated these parameters with conventionally accepted prognostic factors (lymphovascular invasion, T and N staging) in a large discovery dataset, which was subsequently validated by multivariate modeling in a larger cohort of stage II/ΙΙΙ CRC patients in the QUASAR 2 clinical trial [9].